rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

NexGel, Inc

NXGL · Nasdaq

Health CareMedical DevicesNot moving yet

NXGL stood above a rising 150-day average in 0 of the last 52 weekly readings. It is 43.4% below that average now. Medical Devices: 29% of its 181 stocks in an uptrend (−5 points in four weeks); Health Care: 28% (−9 points in four weeks).

Statistics

Rotation
Not moving yet
Weeks in an uptrend
out for 52
Industry in uptrend
29% -5 in 4 wk
Insider buys, 12 months
$0
Insider sales, 12 months
$68K
Officials’ trades on record
0
Institutions holding
16 (+2)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 0 of 52 weeks.

21 Apr – 20 Oct
19%29%39%Apr 26Jun 26Jul 26Sep 26Oct 26

Medical Devices: A minority of its stocks are in an uptrend and the share has been slipping. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
−$25K$0$103KNov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months0
Sale orders, 12 months12
Buyers · sellers0 · 1
WhoDidSharesTraded
Adam R. LevyChief Executive Officersold5,000at $0.593323 Jun 2026filed 23 Jun 2026
Adam R. LevyChief Executive Officersold6,000at $0.592118 Jun 2026filed 23 Jun 2026
Adam R. LevyChief Executive Officersold3,000at $0.613611 Jun 2026filed 15 Jun 2026
Adam R. LevyChief Executive Officersold3,000at $0.5478 Jun 2026filed 9 Jun 2026
Adam R. LevyChief Executive Officersold3,000at $0.59364 Jun 2026filed 9 Jun 2026
Adam R. LevyChief Executive Officersold2,000at $0.58591 Jun 2026filed 3 Jun 2026
Adam R. LevyChief Executive Officersold3,000at $0.600329 May 2026filed 29 May 2026
Adam R. LevyChief Executive Officersold7,000at $0.605828 May 2026filed 29 May 2026
Adam R. LevyChief Executive Officersold3,000at $0.597527 May 2026filed 29 May 2026
Adam R. LevyChief Executive Officerbought100,000at $0.6014 May 2026filed 18 May 2026
Adam R. LevyChief Executive Officerbought50,000at $0.0014 May 2026filed 18 May 2026
Scott Robert HenryDirectorbought41,667at $0.6014 May 2026filed 18 May 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders16+2 on the quarter
New · exited7 · 5
Reported value$219K

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
SUSQUEHANNA INTERNATIONAL GROUP, LLPnew · filed 14 Aug 202685,140$43K+85,140
GEODE CAPITAL MANAGEMENT, LLCreduced · filed 12 Aug 202671,863$36K-56,673−44.1%
MORGAN STANLEYunchanged · filed 13 Aug 202654,980$28K00.0%
VANGUARD CAPITAL MANAGEMENT LLCnew · filed 13 Aug 202648,920$25K+48,920
CITADEL ADVISORS LLCnew · filed 14 Aug 202640,976$21K+40,976
VANGUARD FIDUCIARY TRUST COnew · filed 13 Aug 202634,040$17K+34,040
UBS Group AGadded · filed 13 Aug 202624,735$12K+18,101+272.9%
JANE STREET GROUP, LLCreduced · filed 14 Aug 202620,606$10K-21,532−51.1%
STATE STREET CORPunchanged · filed 7 Aug 202617,259$8,64700.0%
NORTHERN TRUST CORPnew · filed 13 Aug 202613,431$6,729+13,431
31 Mar 2023 – 30 Jun 2026
71319Mar 23Dec 23Dec 24Sep 25Jun 26

Everyone who traded it

Adam R. Levy Company insiderChief Executive Officer · last 23 Jul 20262 · 25
Scott Robert Henry Company insiderDirector · last 14 May 202614 · 10
Brian Joseph Kieser Company insiderDirector · last 11 May 20260 · 0
Jerome B. Zeldis Company insiderDirector · last 25 Jun 20255 · 0
John Nachum Stein Company insiderDirector · last 25 Jun 202515 · 0
Steven Mark Glassman Company insiderDirector · last 25 Jun 20257 · 0
Adam E. Drapczuk III Company insiderChief Financial Officer · last 20 Nov 20245 · 0
David Stefansky Company insiderDirector · last 17 Aug 202312 · 0
Miranda Jayne Toledano Company insiderDirector · last 17 Aug 20231 · 0
Yaakov Spinrad Company insiderDirector · last 30 Aug 20221 · 0

Same industry

RCEL Avita MedicalLeading+108%
HTFL HeartflowLeading+59%
ATRC AtriCureLeading+52%
HAE HaemoneticsLeading+47%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Profit per saleFY 2025 · to 31 Dec 202539.5%
Operating profit marginFY 2025 · to 31 Dec 2025-29.3%
Free cash flow marginFY 2025 · to 31 Dec 2025-12.1%
Return on capital employedFY 2025 · to 31 Dec 2025-44.7%
Debt to equityFY 2025 · to 31 Dec 20250.13×
Research spendFY 2025 · to 31 Dec 20250.0%
Share count trendFY 2025 · to 31 Mar 20264.1%
Free cash flowFY 2025 · to 31 Dec 2025−$1.4M

Analyst forecasts

No analyst forecasts yet.